CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

NCT06365671 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

OTHER: autologous stem-cell transplantation
DRUG: Relmacabtagene autoleucel (relma-cel)

Sponsor

Ruijin Hospital